Back

LDL-C levels on statins and cardiovascular event risk in stable coronary artery disease: An observation from the REAL-CAD study.

31 August 2019 (11:00 - 16:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Acute coronary syndromes, coronary artery disease: treatment Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Toshiaki Toyota

Kobe City Medical Center General Hospital, Kobe (Japan)

16 More presentations in this session

Presentation thumbnail
Doctor K. Svendsen (Oslo, NO)
Abstract Slides
Presentation thumbnail
Doctor R. CHEN (Beijing, CN)
Abstract Slides
Presentation thumbnail
Associate Professor K. Dyrbus (Zabrze, PL)
Abstract Slides
Presentation thumbnail
Doctor A. Mahabadi (Essen, DE)
Abstract
Presentation thumbnail
Doctor C. Kissel (Zurich, CH)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Acute coronary syndromes, coronary artery disease: treatment

The Event

Event poster

ESC Congress 2019

31 August 2019 11:00 CET
You may be interested in
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
Impact of lipoprotein(a) as a residual risk on long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statin
27 August 2021
thumbnail
Congress Presentation
Plaque characteristics in patients with very low low-density lipoprotein cholesterol levels not treated with statins: an intracoronary optical coherence tomography study
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources